Breaking Finance News

Numis disclosed Horizon Discovery Group Plc (LON:HZD), supporting its price target at 260.00GBX earlier today

Boasting a price of 156.50GBX, Horizon Discovery Group Plc (LON:HZD) traded -0.64% lower on the day. With the last close down -3.56% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Horizon Discovery Group Plc has recorded a 50-day average of 160.33GBX and a two hundred day average of 160.73GBX. Volume of trade was down over the average, with 133,309 shares of HZD changing hands under the typical 178,655

Numis hold steady the target of Horizon Discovery Group Plc (LON:HZD) at 260.00GBX stating a potential upside of 0.66%.

On 9/20/2016, N+1 Singer released a statement on Horizon Discovery Group Plc (LON:HZD) maintained the target price at 194.00GBX that suggested an upside of 0.27%.

Performance Chart

Horizon Discovery Group Plc (LON:HZD)

With a total market value of 0 GBX, Horizon Discovery Group Plc has with a one year low of 125.00GBX and a one year high of 188.06GBX .

A total of 3 analysts have released a research note on HZD. One analyst rating the company a strong buy, two analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of 218.67GBX.

More About Horizon Discovery Group Plc (LON:HZD)

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company's gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1,400 organizations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers, as well as in the Company's own research R&D pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.